Table 4.
NK-cell function during and following treatment with tofacitinib.
| Median (range) | |||||
|---|---|---|---|---|---|
|
| |||||
| Baseline | Day 15 | Day 29 | Day 14 post-treatment |
Day 28 post-treatment |
|
| CD107a + NK cells following stimulation by K562 cells (%) | 12.70 (5.56–26.05) |
13.81 (4.45–27.96) |
10.80 (4.37–29.90) |
13.16 (3.84–32.80) |
10.44*** (4.02–23.62) |
| IFN-γ + NK cells following stimulation by K562 cells (%) | 8.48 (2.79–19.71) |
8.17 (3.07–18.86) |
7.58* (1.78–14.35) |
7.66 (0.56–18.14) |
6.15** (1.49–18.18) |
| CD107a + NK cells following rituximab-induced ADCC (%) | 5.32 (1.08–27.69) |
4.23* (0.18–16.50) |
4.82 (0.52–19.23) |
4.77 (0.97–26.50) |
3.07**†† (0.08–25.27) |
Test statistics are based on log-transformed data.
ADCC, antibody-dependent cell-mediated cytotoxicity; CD, cluster of differentiation; IFN-γ, interferon-gamma; NK, natural killer.
*
p < 0.05,
**
p < 0.001,
***
p < 0.0001 compared with baseline,
††
p < 0.001 compared with Day 29.